{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05027919",
            "orgStudyIdInfo": {
                "id": "IRB00279895"
            },
            "secondaryIdInfos": [
                {
                    "id": "1R01DA052937",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1R01DA052937"
                }
            ],
            "organization": {
                "fullName": "Johns Hopkins University",
                "class": "OTHER"
            },
            "briefTitle": "Assessing a Clinically-meaningful Opioid Withdrawal Phenotype",
            "officialTitle": "Assessing a Clinically-meaningful Opioid Withdrawal Phenotype",
            "therapeuticArea": [
                "Other"
            ],
            "study": "assessing-a-clinically-meaningful-opioid-withdrawal-phenotype"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-24",
            "studyFirstSubmitQcDate": "2021-08-24",
            "studyFirstPostDateStruct": {
                "date": "2021-08-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Johns Hopkins University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.",
            "detailedDescription": "Individuals who have opioid use disorder and are interested in being tapered off of opioids will be admitted to a residential research unit for an 11-day period. All participants will be maintained on morphine for 5 days. During this period participants will complete 2 sessions (on two different days) wherein participants will receive an intramuscular injection of naloxone to precipitate a short withdrawal syndrome. Participants will take a capsule prior to both sessions that will contain either placebo or the opioid withdrawal medication lofexidine. Beginning on day 6 participants will be tapered off of morphine using lofexidine (as clinically indicated). At the end of the study all participants will be able to transition to buprenorphine maintenance or receive oral naltrexone and an injection of Vivitrol (extended release naltrexone), consistent with standard of care practices. Investigators will collect a variety of biological samples and questionnaire ratings during the study and primary outcomes will be measures of withdrawal collected throughout the study. Investigators will use these data to learn more about why individuals express opioid withdrawal symptoms differently, which will help inform how to change current treatment practices to be more effective for persons with OUD."
        },
        "conditionsModule": {
            "conditions": [
                "Opioid Withdrawal",
                "Opioid Use Disorder",
                "Opioid Craving"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "The order of medication pre-treatment during the two Naloxone Challenges will be blinded to participants and the investigator."
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Within-subject design",
                    "type": "OTHER",
                    "description": "All participants will undergo the same study design, which includes morphine stabilization (days 1-5), two naloxone challenges (scheduled during morphine stabilization), lofexidine-assisted taper (days 6-10), and transition to aftercare (day 11).",
                    "interventionNames": [
                        "Drug: Morphine",
                        "Drug: Naloxone + lofexidine pretreatment",
                        "Drug: Naloxone + placebo pretreatment",
                        "Drug: Lofexidine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Morphine",
                    "description": "30mg subcutaneous injections of morphine 4 times daily on days 1 through 5.",
                    "armGroupLabels": [
                        "Within-subject design"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Naloxone + lofexidine pretreatment",
                    "description": "0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)",
                    "armGroupLabels": [
                        "Within-subject design"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Naloxone + placebo pretreatment",
                    "description": "0.4mg naloxone injection during the Naloxone challenge",
                    "armGroupLabels": [
                        "Within-subject design"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Lofexidine",
                    "description": "Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.",
                    "armGroupLabels": [
                        "Within-subject design"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Withdrawal severity during lofexidine taper",
                    "description": "Withdrawal severity as assessed by the Subjective Opioid Withdrawal Scale. (The score range is 0 through 64) with higher score indicating more severe withdrawal.",
                    "timeFrame": "Days 6 through 10"
                },
                {
                    "measure": "Withdrawal severity during naloxone challenge",
                    "description": "Withdrawal severity as assessed by the Subjective Opioid Withdrawal scale scores (The range is 0 through 64) with higher score indicating more severe withdrawal. Collected during two naloxone challenges (pretreatment with lofexidine and pretreatment with placebo).",
                    "timeFrame": "Days 1 through 5"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years - 65 year old\n* Opioid-positive urine sample\n* Current opioid use disorder with evidence of physical dependence\n* Interest in undergoing opioid taper\n\nExclusion Criteria:\n\n* Evidence of physical dependence on alcohol or benzodiazepines that requires medical intervention\n* Being pregnant or breastfeeding\n* Enrolled in methadone or buprenorphine maintenance treatment\n* Clinically significant hypotension (\\<90/60mmHg) or bradycardia (\\<45bpm)\n* History of myocardial infarction\n* Subjects who are positive for hepatitis B surface antigen and/or hepatitis C antibody with liver function tests outside the normal range (persons with a positive hepatitis C antibody and normal liver functions tests are NOT excluded from the study)\n* Significant mental health or physical disorder, or life circumstances, that is expected to interfere with study participation",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kelly E Dunn, Ph.D, M.B.A.",
                    "role": "CONTACT",
                    "phone": "410-550-2254",
                    "email": "kdunn9@jhmi.edu"
                },
                {
                    "name": "Breanna Labos",
                    "role": "CONTACT",
                    "email": "blabos1@jhmi.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kelly E Dunn, Ph.D, M.B.A.",
                    "affiliation": "Johns Hopkins University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Johns Hopkins University Bayview Medical Campus",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kelly E Dunn, PhD, MBA",
                            "role": "CONTACT",
                            "phone": "410-550-2254",
                            "email": "kdunn@jhmi.edu"
                        },
                        {
                            "name": "Kelly E Dunn, PhD, MBA",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                },
                {
                    "id": "D000013375",
                    "term": "Substance Withdrawal Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Opioid Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M16162",
                    "name": "Substance Withdrawal Syndrome",
                    "asFound": "Opioid Withdrawal",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000025655",
                    "term": "Lofexidine"
                },
                {
                    "id": "D000003000",
                    "term": "Clonidine"
                },
                {
                    "id": "D000009020",
                    "term": "Morphine"
                },
                {
                    "id": "D000009270",
                    "term": "Naloxone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000701",
                    "term": "Analgesics, Opioid"
                },
                {
                    "id": "D000009294",
                    "term": "Narcotics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                },
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000058647",
                    "term": "Adrenergic alpha-2 Receptor Agonists"
                },
                {
                    "id": "D000000316",
                    "term": "Adrenergic alpha-Agonists"
                },
                {
                    "id": "D000000322",
                    "term": "Adrenergic Agonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000013565",
                    "term": "Sympatholytics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M11982",
                    "name": "Morphine",
                    "asFound": "400",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12221",
                    "name": "Naloxone",
                    "asFound": "Adapted",
                    "relevance": "HIGH"
                },
                {
                    "id": "M289447",
                    "name": "Lofexidine",
                    "asFound": "Vestibular Rehabilitation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6232",
                    "name": "Clonidine",
                    "asFound": "Vestibular Rehabilitation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M3668",
                    "name": "Adrenergic alpha-Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3673",
                    "name": "Adrenergic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M16344",
                    "name": "Sympatholytics",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                },
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                }
            ]
        }
    },
    "hasResults": false
}